All News
Filter News
Found 305 articles
-
NRx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
9/7/2023
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that Stephen Willard, J.D., Chief Executive Officer and Dr. Jonathan Javitt, Chief Scientist of NRx Pharmaceuticals, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference.
-
NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens
9/6/2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate potent in vitro activity of NRX-101 (D-cycloserine + lurasidone) against reference strains of Urinary Tract pathogens known to cause complicated urinary tract infections (cUTIs).
-
NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M
9/6/2023
NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement.
-
NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain
8/30/2023
NRx Pharmaceuticals, Inc. announced submission an Investigational New Drug application to the U.S. Food and Drug Administration for the use of NRX-101 to treat Chronic Pain.
-
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share
8/29/2023
NRx Pharmaceuticals, Inc. announced that it entered into a definitive purchase agreement subject to standard closing conditions with accredited investors to purchase 3,000,000 shares of preferred stock at $0.40 per share, which will convert, after six months into 3,000,000 common shares and 3,000,000 warrants to purchase common stock at a purchase price of $0.40 per share; the term on these warrants is five years.
-
NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/28/2023
NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is pleased to announce the filings of its financial results for the quarter ended June 30, 2023 and provide a corporate update.
-
With a potential $509 billion up for grabs by 2028, companies including Biogen, Sage, Karuna Therapeutics and Cerevel Therapeutics are vying to bring their drugs across the regulatory finish line.
-
NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
8/14/2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2023, and provided a business update.
-
NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023
8/7/2023
NRx Pharmaceuticals, Inc., a late-stage biopharmaceutical company, announced that it will release its second quarter 2023 financial results after the market closes on Monday, August 14, 2023, via press release, which will be available on the Company's website.
-
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain
8/7/2023
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced it has made key advances in developing NRX-101 to treat Chronic Pain.
-
NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery
7/20/2023
NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality. Leveraging its proprietary and patented 3D-Flow production, the Company has achieved significantly enhanced EV functionality.
-
Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone's Intranasal ExoPTEN
6/22/2023
NurExone Biologic Inc., is pleased to report positive imaging results from an internal preclinical study of its investigational drug ExoPTEN.
-
NRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
6/20/2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") today announced that Stephen Willard, J.D., Chief Executive Officer and Dr. Jonathan Javitt, Chief Scientist of NRx Pharmaceuticals, will present a company overview at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference.
-
NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering
6/9/2023
NRx Pharmaceuticals, Inc. today announced that it has closed its previously announced registered direct offering for the purchase and sale of 9,670,002 shares of common stock at a purchase price of $0.65 per share of common stock.
-
NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering
6/6/2023
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has entered into definitive agreements for the purchase and sale of 9,670,002 shares of common stock at a purchase price of $0.65 per share of common stock in a registered direct offering.
-
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101
6/5/2023
Lotus Pharmaceuticals (1795:TT; “Lotus”) and NRx Pharmaceuticals Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals or NRx”), a clinical stage biopharmaceutical company, today announced a global collaboration agreement covering the development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets.
-
NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023
6/2/2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update conference call on Monday, June 5, 2023 at 8:30 a.m. EDT.
-
NurExone and Particle Metrix Announce Collaboration in Extracellular Vesicles Analysis Using State-of-the-art Analytic Device
6/1/2023
NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce a pioneering collaboration with the German company, Particle Metrix, a leading provider of particle analysis devices.
-
NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/24/2023
NurExone Biologic Inc. has released its financial results for the quarter ended March 31, 2023.
-
NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries
5/16/2023
NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90) (NRX.V) announces that the Company has received an issue notification from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent NO. 11,648,260, granted for the period of 20 years from filing date until March 27, 2039.